4DMT Announces Presentations at ARVO 2024 Annual Meeting
01 5월 2024 - 9:00PM
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company),
a leading clinical-stage genetic medicines company focused on
unlocking the full potential of genetic medicines to treat large
market diseases, today announced presentations at the 2024
Association for Research in Vision and Ophthalmology (ARVO) Annual
Meeting in Seattle, Washington on May 5-9, 2024.
2024 ARVO Annual Meeting Presentation
Details:
Title: |
Interim results from the PRISM randomized Phase 2 Dose Expansion
trial evaluating 4D-150 in high anti-VEGF need individuals with
neovascular (wet) age-related macular degeneration |
Poster Session: |
AMD-3 (clinical research), 416 (Poster A0075) |
Date/Time: |
Wednesday, May 8, 2024 (10:30 a.m. PT) |
Presenter: |
Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research
at Sierra Eye Associates, Clinical Associate Professor at
University of Nevada, Reno School of Medicine |
Title: |
Preclinical characterization of 4D-175, a novel AAV-based
investigational intravitreal gene therapy for geographic
atrophy |
Paper (Oral) Session: |
AMD: Translational studies, 522 |
Date/Time: |
Thursday, May 9, 2024 (12:00 p.m. PT) |
Presenter: |
Melissa A. Calton, Ph.D., VP, Early-Stage Product Development at
4DMT |
The presentations will also be available on the 4DMT website
under Scientific Presentations:
https://4dmoleculartherapeutics.com/pipeline/#posters-and-publications
About 4DMT
4DMT is a leading clinical-stage genetic medicines company
focused on unlocking the full potential of genetic medicines to
treat large market diseases in ophthalmology and pulmonology.
4DMT’s proprietary invention platform, Therapeutic Vector
Evolution, combines the power of the Nobel Prize-winning
technology, directed evolution, with approximately one billion
synthetic AAV capsid-derived sequences to invent customized and
evolved vectors for use in our wholly owned and partnered product
candidates. Our product design, development, and manufacturing
engine help us efficiently create and advance our diverse product
pipeline with the goal of revolutionizing medicine with potential
curative therapies for millions of patients. Currently, 4DMT is
advancing five clinical-stage and two preclinical product
candidates, each tailored to address rare and large market diseases
in ophthalmology, pulmonology, and cardiology. In addition, 4DMT is
also advancing programs in CNS through a gene editing partnership.
4D Molecular Therapeutics™, 4DMT®, 4D®, Therapeutic Vector
Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of our product candidates are in clinical or preclinical
development and have not yet been approved for marketing by the FDA
or any other regulatory authority. No representation is made as to
the safety or effectiveness of our product candidates for the
therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Katherine SmithInizio Evoke
CommsKatherine.Smith@inizioevoke.com
Investors:
Julian PeiHead of Investor Relations and Corporate
FinanceInvestor.Relations@4DMT.com
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
4D Molecular Therapeutics (NASDAQ:FDMT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024